Sendai, Japan

Eiichi Kodama

This inventor holds 1 USPTO granted patent. Top assignee: Fujifilm Corporation. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eiichi Kodama. Retrieved from https://idiyas.com/inventor/eiichi-kodama-9nhcq4of

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eiichi Kodama: Innovator in Anti-Adenoviral Agents

Introduction

Eiichi Kodama is a notable inventor based in Sendai, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that exhibit excellent drug efficacy.

Latest Patents

Kodama holds a patent for a cyclobutyl purine derivative or salt thereof. The objective of this invention is to provide a compound that serves as an effective anti-adenoviral agent. The patent presents a compound represented by General Formula [1], showcasing its potential in combating adenoviral infections.

Career Highlights

Kodama is associated with Fujifilm Corporation, where he has been involved in innovative research and development. His work focuses on creating effective pharmaceutical solutions that address critical health challenges.

Collaborations

Kodama has collaborated with esteemed colleagues, including Hidenobu Kuniyoshi and Takehiro Yamane. Their combined expertise has contributed to advancing research in the field of antiviral agents.

Conclusion

Eiichi Kodama's work in developing anti-adenoviral agents highlights his commitment to improving healthcare through innovation. His contributions are vital in the ongoing fight against viral infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…